Back to Search
Start Over
Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial
- Publication Year :
- 1991
-
Abstract
- BACKGROUND. GR32191B is a novel thromboxane A2-receptor antagonist with potent antiagregational and antivasoconstrictive properties. We have conducted a randomized, double-blind placebo-controlled trial to study its usefulness in restenosis prevention. METHODS AND RESULTS. Patients received either GR32191B (80 mg orally before angioplasty and 80 mg/day orally for 6 months) or 250 mg i.v. aspirin befo
Details
- Database :
- OAIster
- Notes :
- application/pdf, Circulation (Baltimore) vol. 84, pp. 1568-1580, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.ocn929983505
- Document Type :
- Electronic Resource